Table 2.
Organ Involvement/Manifestations for Patients With Sarcoidosis in Initial Cohorts
| Organ Involvement/Manifestation | Biopsy | Highly Probable | At Least Probable | Total Having ≥ 1 Feature |
|---|---|---|---|---|
| Lung | 296 (65.8) | 294 (65.3) | 148 (32.9) | 386 (85.8) |
| Skin | 80 (17.8) | 30 (6.7) | 112 (24.9) | 133 (29.6) |
| Eye | 11 (2.4) | 101 (22.4) | 22 (4.9) | 116 (25.8) |
| Liver | 33 (7.3) | NCE | 61 (13.6) | 61 (13.6) |
| Hypercalcemia/hypercalciuria/nephrolithiasis | NCE | 54 (12.0) | 3 (0.7) | 56 (12.4) |
| Extrathoracic lymph node | 45 (10.0) | NCE | 53 (11.8) | 53 (11.8) |
| Neurologic | 6 (1.3) | 31 (6.9) | 21 (4.7) | 51 (11.3) |
| Spleen | 3 (0.7%) | NCE | 37 (8.2) | 37 (8.2) |
| Cardiac | 0 (0.0) | NCE | 36 (8.0) | 36 (8.0) |
| Bones/joints | 9 (2.0) | 3 (0.7) | 18 (4.0) | 19 (4.2) |
| Ear/nose/throat | 13 (2.9) | NCE | 12 (2.7) | 12 (2.7) |
| Parotid/salivary | 2 (0.4) | 0 (0.0) | 7 (1.6) | 7 (1.6) |
| Bone marrow | 11 (2.4) | 6 (1.3) | NCE | 6 (1.3) |
| Renal | 7 (1.6) | NCE | 5 (1.1) | 5 (1.1) |
| Musclesa | 0 (0.0) | NCE | 0 (0.0) | 0 (0.0) |
| Lofgren syndrome | NCE | 15 (3.3) |
Data are presented as No. (%) unless otherwise indicated. NCE = no criterion established.
a
One patient with possible muscle disease.